# Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects

> **NCT06506175** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Overweight or Obese, Type 2 Diabetes

## Interventions

- **DRUG:** HRS9531 tablets

## Key facts

- **NCT ID:** NCT06506175
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-05
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06506175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06506175, "Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06506175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*